Chemo-Enzymatic PEGylation/POxylation of Murine Interleukin-4
Article 2021 en
Authors
DH
Dorothee Haas
NH
Niklas Hauptstein
MD
Michael Dirauf
Abstract
1 min read
Interleukin-4 (IL-4) is a potentially interesting anti-inflammatory therapeutic, which is rapidly excreted. Therefore, serum half-life extension by polymer conjugation is desirable, which may be done by PEGylation. Here, we use PEtOx as an alternative to PEG for bioconjugate engineering. We genetically extended murine IL-4 (mIL-4) with the d-domain of insulin-like growth factor I (IGF-I), a previously identified substrate of transglutaminase (TG) Factor XIIIa (FXIIIa). Thereby, engineered mIL-4 (mIL-4-TG) became an educt for TG catalyzed C-terminal, site-directed conjugation. This was deployed to enzymatically couple an azide group containing peptide sequence to mIL-4, allowing C-terminal bioconjugation of polyethylene glycol or poly(2-ethyl-2-oxazoline). Both bioconjugates had wild-type potency and alternatively polarized macrophages.
Niklas Hauptstein, Paria Pouyan, Kevin Wittwer, Gizem Cinar, Oliver Scherf‐Clavel, Martina Raschig, Kai Licha, Tessa Lühmann, Ivo Nischang, Ulrich Sigmar Schubert, Christian K. Pfaller, Rainer Haag, Lorenz Meinel
Discussion(0)
No comments yet. Be the first to comment.